Malaria Information and Prophylaxis, by Country [D]

The information presented in this table is consistent 1 with the information in the CDC Health Information for International Travel (the “Yellow Book”).

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Malaria Information and Prophylaxis by Country
Country Areas with Malaria Drug Resistance2 Malaria Species3 Recommended Chemoprophylaxis4 Key Information Needed and Helpful Links to Assess Need for Prophylaxis for Select Countries
Democratic Republic of the Congo (Congo-Kinshasa) All Chloroquine P. falciparum >90%,

P. ovale 5%,

P. vivax rare

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Denmark None Not Applicable Not Applicable Not Applicable
Djibouti All Chloroquine P. falciparum 90%,

P. vivax 5-10%

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Dominica None Not Applicable Not Applicable Not Applicable
Dominican Republic Primarily in the provinces by the border with Haiti, and the provinces (including resort areas) of Santo Domingo and La Altagracia. Rare locally transmitted cases in the city of Santo Domingo (Distrito Nacional) and other provinces. None P. falciparum 100% Provinces bordering Haiti, and provinces of Santo Domingo (except Santo Domingo city [Distrito Nacional]) and La Altagracia: atovaquone-proguanil, chloroquine, doxycycline, mefloquine, or tafenoquine6.
Santo Domingo (Distrito Nacional) city and other provinces: Mosquito avoidance only.

1. Factors that affect local malaria transmission patterns can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection. Information in these tables is updated regularly.
2. Refers to P. falciparum malaria unless otherwise noted.
3. Estimates of malaria species are based on best available data from multiple sources.
4. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
5. This risk estimate is based largely on cases occurring in US military personnel who travel for extended periods of time with unique itineraries that likely do not reflect the risk for the average US traveler.
6. Primaquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients must be screened for G6PD deficiency prior to starting primaquine.

Page last reviewed: February 28, 2019